Clinical Trial Update: Graz Osteoprotegerin as a Risk Factor (GORF) Study

View source ↗

Summary

The GORF study update describes investigation of osteoprotegerin (OPG) and RANKL as risk factors in patients with coronary artery disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Snippet

Sponsor: Medical University of Graz | Conditions: Prevalent OPG and RANKL Excession in Patients With CAD | Status: UNKNOWN